Search clinical trials for: insulin glargine glulisine

Total 2833 results

University of Pittsburgh
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Completed

Health Care for Type 1 Diabetes in Developing World

Type 1 Diabetes

Rwanda
Sanofi

Completed

Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes Mellitus

Germany
Sanofi

Completed

Insulin Glargine During and After the Period of Fasting in Ramadan

Diabetes Mellitus, Type 2
US Department of Veterans Affairs

Completed

Insulin Secretion in Diabetes Before and After Glycemic Control

Hyperglycemia | Diabetes

United States
Eli Lilly and Company

Terminated

Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin (HMH)

Hyperglycemia

United States
Changhua Christian Hospital

Recruiting

Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care

Diabetic Ketoacidosis | Hyperglycaemic Crisis in Diabetes Mellitus | Hyperglycaemic Hyperosmolar Nonketotic Syndrome

Taiwan
University Hospital Tuebingen

Terminated

Effects of Insulin Glargine and Lixisenatide on the Brain (Lixibrain01)

Diabetes Mellitus, Type 2

Germany
Pfizer

Completed

A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®

Diabetes Mellitus, Type 2

Germany, Netherlands, Sweden, Poland, Belgium, Finland, France, Norway, Spain, Switzerland
Mylan Inc.
Mylan GmbH

Completed

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2) (INSTRIDE 2)

Type 2 Diabetes

United States, Jordan, Korea, Republic of, Slovakia, South Africa, Taiwan
Eli Lilly and Company

Completed

A Study of LY2605541 Versus Insulin Glargine on Blood Sugar

Diabetes Mellitus, Type 1 | Healthy Volunteers

United States
Sanofi

Completed

Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin

Diabetes Mellitus, Type 2

United States
John H. Stroger Hospital
Eli Lilly and Company

Completed

Insulin Therapy in the Hospital Comparing Two Protocols

Diabetes Mellitus, Type 2

United States
Eli Lilly and Company

Completed

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections (QWINT-4)

Type 2 Diabetes | Type 2 Diabetes Treated With Insulin

United States, Germany, Mexico, Argentina, Puerto Rico, Italy, Spain, India
Sanofi

Completed

Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old. (Lantus-P-CN)

Type 1 Diabetes Mellitus

China
Rabin Medical Center

Unknown

Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department

DM2
Hallym University Medical Center

Completed

Insulin Dose Titration System Using a Short Messaging Service (SMS) Automatically Produced by a Knowledge Matrix

Diabetes Mellitus, Type 2
Sanofi

Completed

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine (GEMELLI1)

Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus

Hungary, Russian Federation, Germany, Poland, Japan, United States, Finland
Kinderkrankenhaus auf der Bult
Sanofi

Completed

Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) (LAS)

Type 1 Diabetes | Lipoatrophy
University of Aarhus
Novo Nordisk A/S; The Danish Diabetes Association; The Institute of Experimental...

Completed

Basal Insulins - Pharmacodynamics

Diabetes

Denmark
Charles Drew University of Medicine and Science
National Center for Research Resources (NCRR)

Completed

Insulin Glargine at Bedtime or in AM Versus NPH

Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Healthy Volunteers

Germany
Sanofi

Completed

Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment (Transition II)

Diabetes Mellitus, Type 2

France
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Sanofi

Completed

Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine) (GALATEE)

Type 2 Diabetes

France
Skane University Hospital
Medical Research Council; Skane County Council Research & Development Foundation

Completed

Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes

Type 2 Diabetes | Secondary Drug Failure

Sweden
Novo Nordisk A/S

Completed

Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Spain, France, Norway, Romania
Sanofi

Completed

Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL (TOP1)

Type I Diabetes Mellitus

Brazil
Novo Nordisk A/S

Completed

Safety of NNC 0123-0000-0338 in Healthy Subjects

Healthy | Diabetes

Germany
Eli Lilly and Company

Completed

Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX) (IOOX)

Diabetes Mellitus, Type 2

Australia, Russian Federation, Spain, Mexico, Canada, France, Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168)

Diabetes
Mount Sinai Hospital, Canada
Canadian Institutes of Health Research (CIHR)

Completed

Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Pilot Study)

Type 2 Diabetes

Canada
Eli Lilly and Company

Completed

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) (IOOV)

Diabetes Mellitus, Type 2

United States, Canada, India, Puerto Rico, Australia, Spain, Netherlands, Hungary, Brazil, Greece, Romania, Argentina
Sanofi

Completed

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

United States, Chile, Czech Republic, Denmark, France, Germany, Hungary, Lithuania, Mexico, Poland, Romania, Slovakia, Sweden
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes (EUROMIX)

Diabetes Mellitus, Type 2 | Diabetes

Austria, Hungary, Slovenia, Germany, Czech Republic, Poland, Slovakia
Amsterdam UMC, location VUmc

Completed

Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure

Type 2 Diabetes Mellitus | Congestive Heart Failure

Netherlands
The Cleveland Clinic

Terminated

Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management

Type 1 Diabetes | Type 2 Diabetes | Diabetic Ketoacidosis

United States
Mira Zuidgeest
Sanofi; Innovative Medicines Initiative; IMI Trials@Home consortium

Active, not recruiting

Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL) (RADIAL)

Diabetes Mellitus, Type 2

Germany, United Kingdom, Denmark
Eli Lilly and Company

Completed

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus (AWARD-CHN2)

Type 2 Diabetes Mellitus

China, Mexico, Korea, Republic of, Russian Federation
Sanofi

Completed

Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus (PUMP)

Diabetes Mellitus, Type 1

France, Australia, Spain, Sweden, United States, Austria, Hungary, Israel, Italy, United Kingdom, Korea, Republic of, Netherlands
Eli Lilly and Company

Completed

A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Taiwan, China, Korea, Republic of
Sanofi

Active, not recruiting

Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs (SAFEGUARD)

Type 2 Diabetes Mellitus

India
Sanofi

Completed

Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure (GAUDI)

Type 2 Diabetes Mellitus

Japan
University of Maryland, Baltimore

Completed

Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis

Diabetic Ketoacidosis

United States
Medical University of Vienna

Completed

Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin (LixiBIT)

Type 2 Diabetes Mellitus

Austria
Sanofi

Completed

Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus

Type1 Diabetes

Germany
University of Padova

Completed

Endothelial Effects of Basal Insulin: Detemir Versus Glargine

Cardiovascular Disease | Type 2 Diabetes | Endothelial Dysfunction

Italy
Munich Municipal Hospital
Aventis Pharmaceuticals

Unknown

Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD)

Coronary Artery Disease | Type 2 Diabetes

Germany
Northumbria University
Newcastle University

Completed

Combined Basal-bolus Insulin and Post-exercise Carbohydrate Feeding Strategy in T1DM

Type 1 Diabetes Mellitus

United Kingdom
Novo Nordisk A/S

Completed

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

Diabetes Mellitus, Type 2

United States, Poland, Slovakia, Canada, Slovenia, Greece, Czechia

3

Subscribe